https://www.selleckchem.com/
RESULTS Compared to normal controls, patients with ALL exhibited upregulated levels of Bmi-1 (p=0.03). Patients who overexpressed Bmi-1 and NANOG displayed a significantly worse survival than low-expressing patients (hazard ratio (HR) 5.74, 95% confidence interval (CI)1.48-22, p=0.012 and HR 3.8, 95% CI1.009-14.3, p=0.048, respectively). CONCLUSIONS Taken together, these data suggest that the Bmi-1 and NANOG might serve as a novel survival predictor in ALL patients. Our observation also suggests that the Bmi-1 and NANOG could serve as new therapeutic target
Like
Comment
Share
